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Abstract
Introduction and hypothesis Estimation on prevalence and
distribution of pelvic organ prolapse (POP) signs in a
general female population is difficult. We therefore devel-
oped and validated a prediction model and prognostic
instrument.
Methods Questionnaires were sent to a general female
population (45–85 years). A random sample underwent
vaginal examination for POP (POPQ). A prediction model
was developed using multivariate analysis and validated in
a subgroup of participants.
Results Positive questionnaire-response rate was 46.8%
(1,397 of 2,979). From the questionnaire group, 649
women were vaginally examined (46.5%). Prevalence of
clinically relevant POP was 21%. Multivariate analysis
demonstrated significantly higher odds ratios on the report
of vaginal bulging, parity ≥2 and a mother with POP. The
receiver operating characteristic curve showed areas under
the curve of 0.672 and 0.640.
Conclusions The prevalence of POP at or beyond the
hymen could be estimated in a general female population
using our prediction model with 17 questions and our POP
score chart with eight questions.
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Pelvic organ prolapse (POP) is part of a range of conditions
that are related to pelvic floor dysfunction such as urinary
incontinence, bowel disorders and the report of vaginal
bulging [1, 2]. The lifetime prevalence in women of over
50 years of age is 30–50% [3]. Women have an 11–11.8%
chance of undergoing at least one surgical intervention for
POP or incontinence by the age of 79 years, with a re-
operation rate of 29.2% [4, 5]. Complication rates after
surgery in different racial groups were reported to be 19.4%
(white), 34.1% (black) and 27.4% (other) [6]. POP is
therefore associated with a high financial burden on health
care [4]. Although only a relatively small number of
women with POP seek treatment, it is expected that this
number will increase in the future [7]. At present, the direct
cost of POP surgery already exceeds 1 $ billion per year in
the United States alone [8].
To estimate the care requirements of women with POP in
the future, it is important to have reliable prevalence data
from a general female population. Data must be obtained
using a questionnaire and vaginal examination because
there is only a moderate correlation between the signs of
POP (measured by vaginal examination) and the symptoms
(measured by a questionnaire) [9, 10].
To obtain reference data on the prevalence and distribu-
tion of POP signs and the POP symptom of feeling and/or
seeing a vaginal bulge, we conducted a cross-sectional
study on a general population of women aged 45–85 years.
Our first aim was to develop and validate a prediction
model that will be helpful to researchers and health care
policy makers. We focussed on three different cut-off points
because of a discrepancy between feeling and/or seeing a
vaginal bulge (the cornerstone symptom of POP) and the
presence of POP signs in literature. A high correlation
between signs and symptoms can be present when a
different cut-off point is taken regarding the presence of
POP. Therefore, we looked at 1 cm above, at the hymen and
1 cm beyond the hymen. Secondly, we created a POP score
chart and a prognostic index to estimate the presence of
POP in a general population without vaginal examination
and the amount of care needed by women.
Materials and methods
A cross-sectional study was performed on a general
population of women aged 45 to 85 years. A flowchart of
the study design is presented in Fig. 1.
The study population comprised 2,979 women, regis-
tered in the office records of eight out of nine general
practitioners in Brielle. Brielle is a town near Rotterdam
(the Netherlands) with 16,000 citizens. Because all inha-
bitants have the obligation to be registered in a general
practitioners clinic, the study population contained 95% of
all women in Brielle. It has an almost exclusively white
population (98.4%). Names and addresses of all 2,979
eligible women aged 45–85 years were obtained from the
general practitioners. The women were sent information
about the pelvic floor study and could be enrolled by filling
out an informed consent form. They were offered three
options: to sign a refusal form, or to fill out the
questionnaire only or to fill out the questionnaire and
undergo vaginal examination.
All the women were asked to complete a self-report
questionnaire. A reminder, containing the same question-
naire, was sent 8 weeks after the first contact. The data
were collected anonymously. To avoid selection bias, non-
responders were invited to complete a short questionnaire
that comprised five questions about age, parity, presence of
stress urinary incontinence (yes/no), faecal incontinence
(yes/no) and feeling of vaginal bulging (yes/no). To
encourage a high response to the questionnaire, we used
envelopes with the name and logo of the Erasmus
University, coloured paper and stamped-addressed-return
envelopes [11].
The questionnaire used in this study combined several
Dutch validated pelvic floor questionnaires, such as the
Urogenital Distress Inventory [12] and the Defaecation
Distress Inventory [13]. In addition, subjects were asked
about ethnicity, parity, vaginal bulging, incontinence, pelvic
girdle pain and vaginal bulging during pregnancy, family
history, menopausal status, hormone replacement therapy
(HRT), previous pelvic floor surgery, educational level,
smoking and heavy physical work at present or in the past.
Vaginal examination
From all the participants who gave informed consent in the
beginning of the study to undergo vaginal examination (n=
1,140), 800 women were randomly selected by age for
POPQ measurement. (All response forms of the women
were registered with a number that identified the age, and
they were at random taken by a research assistant). The
POPQ was introduced by the International Continence
Society (ICS). It has become widely accepted and proven to
be valid [1] and reliable [14].
A gynaecologist (MV) and a physiotherapist (MS)
performed the vaginal examinations. The two examiners
practiced the POPQ measurement protocol until they
reached agreement about the test and registration scores.
This process was performed at the Pelvic Floor Centre at
the Erasmus Medical Centre in Rotterdam. POPQ measure-
ments were carried out in conformity with the ICS stand-
ardisation report [1]. After each examination, all the details
were entered into the three-by-three POPQ grid. The two
1014 Int Urogynecol J (2009) 20:1013–1021examiners were blinded to the results of the questionnaire.
The women were asked to empty their bladder before the
examination.
Women were assigned to one of five ordinal stages of
prolapse (0–4) in accordance with the POPQ grading
system. All the methods, definitions and descriptions were
in line with the ICS [1].
To make a detailed analysis of stage 2, we divided it into
2A (indicating 1 cm above the hymen), 2B (0) and 2C
(1 cm beyond the hymen). So, for example, the cut-off
point 2A means that all subjects with POP stage 2A till
stage 4 are used for analyses. Within the vaginal examina-
tion group, the women were classified into the symptomatic
group if they reported feeling and/or seeing vaginal
bulging, and all others were included in the asymptomatic
group.
Statistical analysis
Logistic regression was used to develop multivariate
prediction models on the risk of prolapse. Three different
definitions of prolapse were used and compared, based on
the three cut-off points on the POPQ scale 2A, 2B and 2C.
Backwards elimination of the predictors was used. Varia-
Women 45-85 years 
n=2979 
Invited for study   
informed consent 
Responders  
n=1869 
62.7% 
Moved/died 
 n=59 
2% 
Non-responders  
n=1051 
35.2% 
Short questionnaire 
n=1051 
Non-responders 
n=431 
Responders n=620  
n=579 controls,  
n=41 symp 
No agreement 
n=472 
15.8% 
Agreement  on 
questionnaire 
n=1397 
46.8% 
Agreement on vaginal 
palpation n=1140 38.2%
random selected 
n= 800 26.8%
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5% 
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n=649  
21.7% 
Included 
(quest + vaginal exam)
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 n=79 
2.6% 
Group 1
Group 2 
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Fig. 1 Flowchart of the study
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eliminates most of the purely random variables and
improves the chance that the model will perform well in
future patients [15]. The predictive performance of the three
resulting models was transformed into receiver operating
characteristic (ROC) curves and the areas under the curves
(AUC) were compared. There was a limited number of
missing values on many of the variables. As multivariate
analysis is severely hampered by missing values and more
importantly, results may be biassed, we used multiple
imputation with ten datasets [16].
Internal validation of the models was performed by a
bootstrap re-sampling procedure: the model building
process was repeated 200 times after creating 200 new
datasets (bootstrap samples) by randomly drawing cases
(with replacement) from the original data. The variable
selection and estimation procedure was performed on each
bootstrap sample. This yielded 200 sets of predictors and
parameter estimates. The model estimates of each bootstrap
sample were evaluated on the basis of the original data. On
average, the predicted and observed outcomes should agree.
Predictions that deviate strongly from the mean usually
differ greatly from the observed outcomes due to over-
fitting of the model. The size of the over- fitting effect was
estimated by averaging the 200 bootstrap samples. This
produced a shrinkage factor c to compensate for the over-
fitting [17]. The bootstrap method was also used to estimate
the amount of optimism in the AUC by optimally fine-
tuning a model and subsequently evaluating its predictive
performance on the same data [17].
The prediction model that showed the highest AUC was
translated into a pragmatic prognostic score, the Slieker
POP score. For each prognostic factor in the model, the
regression coefficients in the logistic model were converted
into score points. For ease of use, the regression coef-
ficients were scaled and rounded to whole numbers, such
that the minimum and maximum score of women in our
data set were 0 and 100, respectively. From a graph, the
corresponding risk of POP can be read off.
The analyses were performed using the Statistical
Package for Social Science (SPSS) 15.0. The Medical
Ethics Research Committee of the Erasmus Medical Centre
in Rotterdam, the Netherlands, approved this study.
Results
Response rate
The response rate to the questionnaire was 62.7% (1,869 of
2,979). In the group of 1,869 responders, 472 (15.8%)
women refused to participate, 1,397 (46.8%; group 1)
women agreed to fill out the large questionnaire and 1,140
(38.2%; group 2) agreed to fill out the large questionnaire
and undergo vaginal examination. In the non-responder
group 3, 20.8% returned the completed short questionnaire
(620 of 2,979). Feeling vaginal bulging was reported by
6.7% (n=41) of this non-responder group versus 9.8% in
the responder group (135 of 1,397). From group 2, 800 out
of the 1,140 women who consented to undergo vaginal
examination were selected at random and sent an invitation
for vaginal examination: 649 women participated (81.1%),
which was 21.7% of the total study population and 46.4%
of the women who filled in the questionnaire.
The vaginal examination group of 649 women was
stratified into an asymptomatic control group (n=570) and
a symptomatic (n=79) group in which the women had
reported seeing and/or feeling vaginal bulging. Combining
the data on the large and short questionnaires from the
responders and the initial non-responders (1,397+620=
2,017) revealed the report of a feeling of vaginal bulging
prevalence rate of 8.7% (n=176).
Baseline characteristics
Baseline characteristics of the total study population and
the different groups (group 1 the total group, vaginal
examination group 2 divided into a symptomatic group and
an asymptomatic group and the non-responder group 3) are
shown in Table 1.
No significant differences were found between group 1
and group 3 or between the asymptomatic women and the
symptomatic women in group 2.
The prevalence of POP per POP stage in relation with
the report of vaginal bulging in our general population is
presented in Table 2. The overall prevalence of ≥stage 2B
(all the women with stages 2B, 3 and 4) was 17.5% (114 of
649), of whom 30.7% (35 of 79) had symptoms of vaginal
bulging (n=35).
The results of the multivariate analyses on POP stages
2A, 2B and 2C are shown in Table 3. Significantly higher
odds ratios were found especially in stages 2B (at the
hymen) and 2C (beyond the hymen) for the report of
vaginal bulging (3.80 and 5.47, resp.), for ageing (1.04 and
1.04, resp.), parity of 2 (2.84 and 3.06, resp.), parity of ≥3
(2.63 and 3.33, resp.), and POP in the mother (1.96 and
2.00, resp.). The ROC curve in Fig. 2 shows that the largest
AUC were 0.759 for ‘beyond the hymen’ and 0.723 for ‘at
or beyond the hymen’. The AUC values were corrected for
optimism 0.672 and 0.648, respectively.
Due to small sample sizes, no ORs could be calculated in
the multivariate analyses on HRT, hysterectomy, inconti-
nence during pregnancy and incontinence in the mother. In
Table 4, the Slieker-POP-Score-Chart and POP prognostic
index are presented. The score chart is based on POP stage
2B (and 2C), i.e. POP at or beyond the hymen. After filling
1016 Int Urogynecol J (2009) 20:1013–1021Table 1 Baseline characteristics of the total study population group 1, group 2 who underwent vaginal examination divided into symptomatic and
asymptomatic women expressed as percentages (%) with means and the non-responders who filled out the short-questionnaire group 3
Questionnaire 1,
Group 1 n=1,397
Vaginal exam,
Group 2 n=649
Short questionnaire non-responders,
Group 3 n=620
Characteristics of the study population No bulge Bulge
n=570 n=79 (12.2%)
Mean age (range 45–84) years 58.0 (SD±9.2) 58.0 (SD±8.9) 59.3 (SD±9.1) 59.2
Mean BMI 25.6 (SD±3.9) 25.6±3.7 25.5±3.1
Ethnicity
White 1,351 (98.4) 545 (98.7) 78 (100)
Non-white 20 (1.5) 7 (1.3) 0
Educational level (n=1,374) (n=556) (n=78)
Primary only 139 (9.9) 63 (11.3) 7 (9)
Intermediate 1,039 (75.6) 420 (75.5) 60 (76.9)
Higher 196 (14.3) 73(13.1) 11 (14.1)
(n=1,340) (n=551) (n=78)
Parity, median 2 2 2 2
0 120 (8.9) 46 (8.3) 3 (3.8) 67 (10.6)
1 215 (16) 71 (12.9) 13 (16.6) 102 (16.1)
2 675 (50.3) 273 (49.5) 46 (58.9) 277 (43.6)
≥3 387 (28.8) 161 (29.2) 16 (20.5) 180 (28.3)
Menopausal status (n=1,383) (n=557) (n=79)
(Pre)menopausal 374 (27) 151 (27.1) 16 (20.2)
Postmenopausal 1,009 (72.9) 406 (72.9) 63 (79.7)
(Pre)menopausal with HRT (n=1,361) (n=551) (n=79)
(Pre)menopausal with HRT 24 (1.7) 9 (1.6) 0
Postmenopausal with HRT 63 (4.6) 23 (4.2) 7 (8.9)
Smoking (n=1,382) (n=556) (n=78)
Current smoker 280 (20.2) 117 (21) 16 (20.5)
(n=228) (n=39)
Ever smoker 345 (46.3) 158 (54.8) 25 (64.1)
Incont in pregnancy 342 (25.8) 141 (30.7) 23 (26)
(n=1,328) (n=541) (n=75)
POP in pregnancy 270 (20.3) 113 (20.9) 28 (37.3)
Surgical history (n=1,384) (n=557) (n=79)
Prolapse 103 (7.4) 37 (6.6) 16 (20.2)
Incontinence 47 (3.4) 21 (3.8) 3 (3.9)
Hysterectomy 234 (16.9) 85 (15.3) 20 (25.3)
Family history (n=985) (n=397) (n=44)
Mother POP 359 (26.4) 139 (35) 22 (50)
(n=870) (n=357) (n=41)
Mother UI 258 (29.6) 106 (29.7) 16 (39)
Heavy physical work n=1,381 (n=553) (n=79)
Currently 269 (19.3) 109 (19.7) 18 (22.8)
n=1,384 (n=556) (n=79)
Ever 619 (44.3) 248 (44.6) 39 (49.3)
Int Urogynecol J (2009) 20:1013–1021 1017in the numbers on the score chart, the total score can be
interpreted on the prognostic curve and will give the risk
for the presence of POP in percentages. A shrinkage factor
of 0.63, estimated from the bootstrap validation procedure,
was applied to this model to enable optimal predictive
performance in new subjects.
Discussion
The present study was designed to investigate the preva-
lence of POP in a general female population and to develop
a prediction model based on prognostic factors that could
be considered into a prognostic index.
Prevalence
The distribution of pelvic organ prolapse in this population
indicated that POP was present at or beyond the hymen
(≥stage 2B) in 21% of the women. Within this 21%, 45% of
the women had reported the symptom of seeing and/or
feeling vaginal bulging. If stage 2A had been included, the
prevalence would have increased to 36.4%, which is in line
with the study by Gutman et al. [18]. Our results are also
comparable with those reported in many other studies, but
as yet, no reliable explanation has been put forward for the
discrepancy between POP stage and symptoms of vaginal
bulging [3, 9, 19–21]. Explanations for the discrepancies
between POP signs and POP symptoms might lie in the
personal sphere, such as coping strategies, attitudes and
beliefs, or in the social and economic circumstances, such
as quality of life. We recommend that future research
focuses on these personal and socio-economic factors in
relation with POP.
Another possible underlying factor in the lack of
conformity between the report of the symptom of vaginal
bulging with the signs of POP stage is the reliability of the
POPQ measurement. Results can be influenced by the level
of fullness of the bladder and bowel and by reluctance to
make a maximum valsalva manoeuvre on command during
Table 3 Results of the multivariate logistic regression analysis with test scores and area under the curve (AUC) in POP substages 2A, 2B and 2C
in relation to the hymen (pregn. POP = vaginal bulging symptoms during pregnancy with at least a little bother)
Distance ≥−1, 2A Distance ≥0, 2B Distance ≥1, 2C
OR 95% CI OR 95% CI OR 95% CI
Vaginal bulging 3.05 5.13 1.81 3.80 6.53 2.22 5.47 10.45 2.97
Age (years) 1.04 1.01 1.06 1.04 1.01 1.08
BMI 0.94 0.87 1.02
Nulliparous 1.16 0.31 4.30
1 child 0.44 0.17 1.17 0 0 >1,000
2 children 1.56 0.90 2.69 2.84 1.28 6.30 3.06 0.97 9.70
≥3 children 1.54 0.85 2.78 2.63 1.13 6.11 3.33 1.00 11.00
Postmenopausal status 1.29 0.86 1.94
Smoking current 0.52 0.33 0.82 0.62 0.35 1.09 0.57 0.25 1.31
Inc surgery 2.23 0.92 5.41 2.11 0.83 5.37
Educ level intermediate 0.67 0.39 1.14
Heavy work current 1.32 0.85 2.04 0.56 0.92 2.66 1.53 0.71 3.35
Heavy work past 1.71 0.88 3.32
Pelvic girdle pain 0.54 0.19 1.55
Pregn. POP 1.40 0.95 2.07 1.44 0.89 2.33
Mother POP 1.55 0.99 2.42 1.96 1.22 3.15 2.00 1.00 3.97
Significance level 0.30
Table 2 The prevalence of POP stage in relation to the report of
vaginal bulging in percentage (n); POP data were missing in six
women; vaginal bulging question had not been answered by ten
women)
Vaginal bulging
Symptomatic n=79 Asymptomatic n=570
Stage 0 15.6 (12) 26.3 (146)
Stage 1 20.8 (16) 39 (217)
Stage 2A 18.1 (14) 17.8 (99)
Stage 2B 16.9 (13) 10.1 (56)
Stage 2C 7.8 (6) 3.7 (6)
Stage 3 16.9 (13) 3.1 (17)
Stage 4 3.9 (3) 0
1018 Int Urogynecol J (2009) 20:1013–1021vaginal examination. We tried to standardise the measure-
ments as much as possible to diminish this bias.
Our results are in contrast with a recent study by
Kluivers et al. [22] who were able to distinguish symptom-
atic women with clinically relevant POP from asymptom-
atic women without any clinically relevant POP. These
differences in outcome can be explained on the basis of
population selection in the study by Kluivers et al. [22]
because women were included who were seeking treatment
for one or more pelvic floor disorders at a pelvic floor
centre.
Prediction model
We developed a prediction model that has substantial
sensitivity and specificity to help researchers estimate the
prevalence of clinically relevant POP on a basis of a short
questionnaire alone. To diagnose POP symptoms, we
focused on the report of feeling and/or seeing vaginal
bulging, as cornerstone of the symptom of POP, because in
the literature, other variables such as urinary splinting,
digital manipulation, defaecation disorders and pelvic
heaviness show no correlations with the presence of POP
[21, 23, 24].
In our study, the AUC was analysed based on risk
factors presented in an earlier study [25], such as age, BMI,
parity, menopausal status and HRT, smoking, hysterectomy,
incontinence surgery, education level, heavy physical work
currently or in the past, pelvic girdle pain, incontinence
and/or the report of vaginal bulging during pregnancy and
incontinence or POP in the mother. Highest sensitivity and
specificity were reached using the 2C score ‘beyond the
hymen’ (AUC 0.759). However, the differences between
the AUC of the cut-off points ‘at’ and ‘beyond the hymen’
Table 4 The Slieker-POP-Score Chart and the prognostic index to read the sum score
POP score
Seeing/feeling bulge Yes No
Score 24 0
Age 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85
Score 03691 3 1 6 1 9 2 2 2 5
Children 0 1 2 ≥3
Score 0 3 19 17
Smoking Yes No
Score 0 8
Incontinence surgery Yes No
Score 14 0
Current heavy work Yes No
Score 8 0
POP symptoms gestation Yes No
Score 6 0
Mother with Pop Yes No
Score 12 0
Prognostic index
(SUM score)
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with the area under the curve of the stages 2A, 2B and 2C
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present between signs and symptoms using these cut-off
points. Especially, the report of vaginal bulging, age,
parity ≥2 and POP in the mother contributed to the
sensitivity and specificity of this prediction model.
However, we recommend the use of ‘at or beyond the
hymen’ as the cut-off point during POP examination
instead of ‘beyond the hymen’. Although the AUC was
lower (0.723), the difference was only small, but the
advantage could be the early detection of POP. This
approach might also enhance preventive strategies for
more advanced POP stages [26–29]. Our findings are in
line with Barber et al. [9] who studied the prevalence of
clinically relevant POP (at or beyond the hymen) in what
they referred to as a ‘low risk’ population, which is also
applicable to a general population.
Higher AUC scores (of 0.90) were recently demonstrated
in the study by Robinson et al. [23] with an artificial neural
network in which 20 variables made the largest contribu-
tions to the prediction model, such as age, gravidity, parity,
number of vaginal deliveries, weight of the largest vaginal
delivery, BMI, menstrual status, number of years postmen-
opausal, race, history of chronic disease, hypertension,
diabetes, chronic obstructive pulmonary disease, prior
hysterectomy, prior prolapse or incontinence surgery and
the use of anti-hypertensive’s. In contrast, our study
included family history, smoking behaviour, education,
heavy physical work, pelvic girdle pain and POP symptoms
during pregnancy. Furthermore, the definition of POP was
different in the study by Robinson et al. They defined
clinically relevant POP as ≥2 cm beyond the hymen. The
location of stages 2B and 2C ‘at or beyond the hymen’
was not used in their artificial neural network at all.
Thus, the definition of POP (≥2 cm beyond the hymen)
used by Robinson et al. can account for the high AUC
score.
We developed and validated a simple, inexpensive tool,
the Slieker-POP-Score-Chart, to predict the outcome of
clinically relevant stage 2B (at or beyond the hymen) and
2C (beyond the hymen) POP with AUC scores of 0.640 and
0.672, respectively. This simple self-diagnostic instrument
can also help women to estimate the severity of their POP.
Until now, only a small number of women with POP seek
treatment. Awareness of the potential presence of POP will
encourage to seek advice on how to deal with their
symptoms, or they can be advised to consult a gynaecol-
ogist or a physiotherapist for pelvic floor training [26–29]
before surgery because in our opinion, surgery is not the
only treatment option.
Raising this awareness can also have an adverse effect
on women being more aware of bulging feelings in the
vagina, but if prevention is a goal, detection is important.
Therefore, the Slieker-POP-Score-Chart can not only be
used by midwifes but also on internet or other
informative media and can be used for research to
preventive strategies.
Strengths and limitations
One of the strengths of this study was the use of vaginal
examination in a large cross-sectional design. This large
study population was a subgroup of an even larger group of
95% of all eligible women of Brielle. Because there was no
referral of the general practitioners and women were
addressed directly by mail, there was no strong bias
selection of the group. Another strength was that the results
led to the development of a validated POP score instrument
to estimate the presence of clinically relevant POP on the
basis of eight questions, without the need for vaginal
examination, which could also be helpful in epidemio-
logical studies. Furthermore, this is a self-report instru-
ment that can support a woman’s decision to consult a
physician.
This study also had limitations. A questionnaire can
elicit socially desirable answers, although this was probably
minimal due to the anonymity of responses to the
questionnaire. It can be difficult to identify POP, as the
situation can change over the course of the day, and there is
considerable dependence on performing a maximum Val-
salva manoeuvre. Although women were not selected by
their physician, still, differences in outcome might have
occurred because of selection bias in the population:
women who experienced some POP symptoms could be
more likely to agree for vaginal examination. This could
cause overestimation of the real prevalence of POP.
Conclusion
The prevalence of POP symptoms in a general Dutch
female population was 12.2%. The prevalence of POP,
scored by the POPQ, ‘at or beyond the hymen’ (≥2B) was
17.5% in the overall group. In the symptomatic group,
45.5% had POP stage ≥2B. With the newly developed
prediction model (based on 17 questions) and the Slieker
POP Score Chart (based on eight questions), the risk of
developing POP can be estimated by healthy women
themselves. According to the researchers, the Slieker
POP Score Chart can be used to estimate the prevalence
of POP ‘at or beyond the hymen’ in a general Caucasian
population.
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